Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
Zhang C, Sun YX, Yi DC, Jiang BY, Yan LX, Liu ZD, Peng LS, Zhang WJ, Sun H, Chen ZY, Wang DH, Peng D, Chen SA, Li SQ, Zhang Z, Tan XY, Yang J, Zhao ZY, Zhang WT, Su J, Li YS, Liao RQ, Dong S, Xu CR, Zhou Q, Yang XN, Wu YL, Zhang ZM, Zhong WZ.
Zhang C, et al. Among authors: tan xy.
Cell Rep Med. 2024 Jul 16;5(7):101615. doi: 10.1016/j.xcrm.2024.101615. Epub 2024 Jun 18.
Cell Rep Med. 2024.
PMID: 38897205
Free PMC article.
Clinical Trial.